Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth

Sales of diabetes drug Mounjaro rose 91% to $9.94 billion, beating analysts' estimates, while obesity drug Zepbound brought in $4.93 billion, compared with expectations of $4.73 billion. The two drugs accounted for a 64.7% share of Lilly's revenue in the latest reported quarter.

Strong demand lifted sales volumes across global markets, with Mounjaro driving growth outside the United States and both Mounjaro and Zepbound boosting U.S. sales, although lower realized prices partly offset those gains, Lilly said.

Lilly and Novo dominate the lucrative obesity market. Lilly surpassed a $1 trillion valuation last year, while Novo's newly launched Wegovy pill is quickly gaining traction in its U.S. rollout.

The global market for obesity drugs reached $66 billion in 2025, according to data firm IQVIA. Analysts expect it to hit over $100 billion by 2030 in the U.S. alone.